Nebula Research & Development’s Guardant Health GH Stock Holding History

Nebula Research & Development’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-32,791	Closed	-$1.4M	–	1029
2025 Q1	$1.4M	Sell	32,791 -19,054	-37%	-$822K	0.13%	264
2024 Q4	$1.58M	Buy	51,845 +13,484	+35%	+$379K	0.19%	163
2024 Q3	$880K	Buy	+38,361	New	+$1.09M	0.11%	342
2024 Q2	–	Sell	-70,328	Closed	-$1.45M	–	884
2024 Q1	$1.45M	Buy	70,328 +50,255	+250%	+$1.08M	0.31%	59
2023 Q4	$543K	Buy	20,073 +5,698	+40%	+$149K	0.16%	226
2023 Q3	$426K	Buy	+14,375	New	+$505K	0.22%	169
2023 Q2	–	Sell	-13,574	Closed	-$318K	–	380
2023 Q1	$318K	Buy	+13,574	New	+$388K	0.56%	88

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nebula Research & Development's GH Position: Q2 2025 in Review

Nebula Research & Development sold out of Guardant Health (GH) in Q2 2025, closing a stake of 32,791 shares — an estimated $1.4M sold.

Nebula Research & Development first reported a position in GH in Q1 2023 and held it in 7 quarters. The position peaked at $1.58M in Q4 2024. 364 funds tracked by Wall St. Rank hold GH as of Q2 2025.

Nebula Research & Development reported no remaining Guardant Health position as of Q2 2025 after selling out during the quarter.
Nebula Research & Development sold 32,791 Guardant Health shares in Q2 2025, an estimated $1.4M.
Nebula Research & Development first reported a position in Guardant Health in Q1 2023 and held it in 7 quarters.
Nebula Research & Development's Guardant Health position peaked at $1.58M in Q4 2024.
364 funds tracked by Wall St. Rank held Guardant Health as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.